The cost of bias: Why GLP-1 stigma is a risk you can’t afford to ignore
GLP-1 medications have changed the conversation on obesity. But alongside the breakthroughs, a troubling viewpoint keeps surfacing: that taking them is a shortcut or an “easy way out.” That bias is not harmless. It undermines evidence-based care, discourages people from seeking treatment, and drives up costs for employers and health plans. Bias against GLP-1s is […]